MetaCap

Journey Medical Corporation (DERM)

NASDAQ: DERMHealth CareBiotechnology: Pharmaceutical PreparationsUSD

3.30-0.25 (-7.04%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

DERM stock chart

Technical analysis

Key statistics

All statistics
Market cap
$93.16M
EPS (TTM)
-$0.18
52-week range
3.21 – 9.56
Day range
3.21 – 3.57
Volume / Avg
244.74K / 190.39K
Beta
—

52-week range

$3.21$9.56

DERM stock today

On Nov 20, DERM ended the session at $3.30, shedding $0.25 (7.04%), versus the S&P 500's 3.70% decline. At this level, DERM sits near the bottom of its 52-week range of $3.21 to $9.56: 65.5% below the high, set on Jan 23, 2026 and 2.8% above the low. DERM is down 57.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 55.8%.

Journey Medical has posted a net loss over the last twelve months (EPS of -$0.18), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Journey Medical

Company profile

Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Claude Maraoui
Headquarters
Scottsdale, AZ
Employees
58
IPO year
2021

Financial highlights

Full financials

In fiscal 2025, Journey Medical generated $61.9 million in revenue, up 10.2% from fiscal 2024. Journey Medical reported a net loss of $11.4 million, compared with a loss of $14.7 million a year earlier. Gross margin was 66.2% (up from 62.8%) and operating margin -13.2%.

Journey Medical annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$61.86M$56.13M$79.18M$73.67M$63.13M
Growth+10.20%-29.11%+7.48%+16.69%+41.78%
Net income$-11.43M$-14.67M$-3.85M$-29.63M$-43.99M
EPS (diluted)$-0.47$-0.72$-0.21$-1.69$-4.32

Analyst forecast

Forecast

Consensus (3 analysts)

strong_buy

Avg. price target

$12.75+286.36%

  • Strong buy 0
  • Buy 3
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $12.00High $13.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.09 vs $-0.03
Surprise
-200.00%

DERM news

All DERM news

Journey Medical peers

Health Care sector
DERM peer companies
CompanyPrice% ChgMarket capCompare
CLLSCellectis S.A. ADR0.9209-7.89%$92.76Mvs DERM
CATXPerspective Therapeutics Inc.0.7538-3.85%$91.03Mvs DERM
NRXPNRX Pharmaceuticals Inc.2.15-15.69%$95.31Mvs DERM
PDSBPDS Biotechnology Corporation0.7774-3.70%$95.39Mvs DERM
NTHINeOnc Technologies Holdings Inc.3.15-9.48%$90.88Mvs DERM
NBPNovaBridge Biosciences ADR0.83-5.66%$96.28Mvs DERM
UNCYUnicycive Therapeutics Inc.3.35-5.10%$97.77Mvs DERM
CPIXCumberland Pharmaceuticals Inc.5.84-7.30%$87.57Mvs DERM

Indexes, lists and sector

Journey Medical stock FAQ

What is Journey Medical's stock price today?

DERM last traded at $3.30 as of Nov 20, 4:00 PM EST, down 7.04% on the day. Prices are delayed at least 15 minutes.

Who is Journey Medical's CEO?

Mr. Claude Maraoui is the chief executive officer of Journey Medical Corporation, which has about 58 employees.

What is the DERM 52-week high?

The 52-week high for DERM is $9.56 and the 52-week low is $3.21. The stock is currently 65.5% below its high.

Compare DERM